These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

111 related articles for article (PubMed ID: 17489030)

  • 1. Evaluation of GERD symptoms during therapy. Part I. Development of the new GERD questionnaire ReQuest.
    Bardhan KD; Stanghellini V; Armstrong D; Berghöfer P; Gatz G; Mönnikes H
    Digestion; 2007; 75 Suppl 1():32-40. PubMed ID: 17489030
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Evaluation of GERD symptoms during therapy. Part I. Development of the new GERD questionnaire ReQuest.
    Bardhan KD; Stanghellini V; Armstrong D; Berghöfer P; Gatz G; Mönnikes H
    Digestion; 2004; 69(4):229-37. PubMed ID: 15256829
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Evaluation of GERD symptoms during therapy. Part II. Psychometric evaluation and validation of the new questionnaire ReQuest in erosive GERD.
    Mönnikes H; Bardhan KD; Stanghellini V; Berghöfer P; Bethke TD; Armstrong D
    Digestion; 2007; 75 Suppl 1():41-7. PubMed ID: 17489031
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Look--but also listen! ReQuest: an essay on a new validated scale to assess the outcome of GERD treatment.
    Bardhan KD; Berghöfer P
    Digestion; 2007; 75 Suppl 1():87-100. PubMed ID: 17489037
    [TBL] [Abstract][Full Text] [Related]  

  • 5. ReQuest-- the challenge of quantifying both esophageal and extra-esophageal manifestations of GERD.
    Stanghellini V
    Best Pract Res Clin Gastroenterol; 2004; 18 Suppl():27-30. PubMed ID: 15588792
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Novel measurement of rapid treatment success with ReQuest: first and sustained symptom relief as outcome parameters in patients with endoscopy-negative GERD receiving 20 mg pantoprazole or 20 mg esomeprazole.
    Mönnikes H; Pfaffenberger B; Gatz G; Hein J; Bardhan KD
    Digestion; 2007; 75 Suppl 1():62-8. PubMed ID: 17489034
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pantoprazole 40 mg is as effective as esomeprazole 40 mg to relieve symptoms of gastroesophageal reflux disease after 4 weeks of treatment and superior regarding the prevention of symptomatic relapse.
    Glatzel D; Abdel-Qader M; Gatz G; Pfaffenberger B
    Digestion; 2007; 75 Suppl 1():69-78. PubMed ID: 17489035
    [TBL] [Abstract][Full Text] [Related]  

  • 8. International validation of ReQuest in patients with endoscopy-negative gastro-oesophageal reflux disease.
    Bardhan KD; Stanghellini V; Armstrong D; Berghöfer P; Gatz G; Mönnikes H
    Digestion; 2007; 75 Suppl 1():48-54. PubMed ID: 17489032
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Evaluation of GERD symptoms during therapy. Part II. Psychometric evaluation and validation of the new questionnaire ReQuest in erosive GERD.
    Mönnikes H; Bardhan KD; Stanghellini V; Berghöfer P; Bethke TD; Armstrong D
    Digestion; 2004; 69(4):238-44. PubMed ID: 15256830
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pantoprazole 40 mg is as effective as esomeprazole 40 mg to relieve symptoms of gastroesophageal reflux disease after 4 weeks of treatment and superior regarding the prevention of symptomatic relapse.
    Glatzel D; Abdel-Qader M; Gatz G; Pfaffenberger B
    Digestion; 2006; 74(3-4):145-54. PubMed ID: 17230024
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Novel measurement of rapid treatment success with ReQuest: first and sustained symptom relief as outcome parameters in patients with endoscopy-negative GERD receiving 20 mg pantoprazole or 20 mg esomeprazole.
    Mönnikes H; Pfaffenberger B; Gatz G; Hein J; Bardhan KD
    Digestion; 2005; 71(3):152-8. PubMed ID: 15870503
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Determination of ReQuest-based symptom thresholds to define symptom relief in GERD clinical studies.
    Stanghellini V; Armstrong D; Mönnikes H; Berghöfer P; Gatz G; Bardhan KD
    Digestion; 2005; 71(3):145-51. PubMed ID: 15870502
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Symptom assessment tools for gastroesophageal reflux disease (GERD) treatment.
    Fass R
    J Clin Gastroenterol; 2007; 41(5):437-44. PubMed ID: 17450022
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Determination of ReQuest-based symptom thresholds to define symptom relief in GERD clinical studies.
    Stanghellini V; Armstrong D; Mönnikes H; Berghöfer P; Gatz G; Bardhan KD
    Digestion; 2007; 75 Suppl 1():55-61. PubMed ID: 17489033
    [TBL] [Abstract][Full Text] [Related]  

  • 15. ReQuest: a new questionnaire for the simultaneous evaluation of symptoms and well-being in patients with gastro-oesophageal reflux.
    Ducrotté P; Zerbib F
    Digestion; 2007; 75 Suppl 1():79-86. PubMed ID: 17489036
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The construction of a new evaluative GERD questionnaire--methods and state of the art.
    Armstrong D; Mönnikes H; Bardhan KD; Stanghellini V
    Digestion; 2007; 75 Suppl 1():17-24. PubMed ID: 17489028
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Development and validation of a disease-specific quality of life questionnaire for gastro-oesophageal reflux disease: the GERD-QOL questionnaire.
    Chan Y; Ching JY; Cheung CM; Tsoi KK; Polder-Verkiel S; Pang SH; Quan WL; Kee KM; Chan FK; Sung JJ; Wu JC
    Aliment Pharmacol Ther; 2010 Feb; 31(3):452-60. PubMed ID: 19878152
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Onset of relief of symptoms of gastroesophageal reflux disease: post hoc analysis of two previously published studies comparing pantoprazole 20 mg once daily with nizatidine or ranitidine 150 mg twice daily.
    Haag S; Holtmann G
    Clin Ther; 2010 Apr; 32(4):678-90. PubMed ID: 20435237
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Validation of the GSFQ, a self-administered symptom frequency questionnaire for patients with gastroesophageal reflux disease.
    Paré P; Meyer F; Armstrong D; Pyzyk M; Pericak D; Goeree R
    Can J Gastroenterol; 2003 May; 17(5):307-12. PubMed ID: 12772004
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparison of one-week and two-week empirical trial with a high-dose rabeprazole in non-cardiac chest pain patients.
    Kim JH; Sinn DH; Son HJ; Kim JJ; Rhee JC; Rhee PL
    J Gastroenterol Hepatol; 2009 Sep; 24(9):1504-9. PubMed ID: 19467139
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.